Category: antifungal

  • Cidara and Mundipharma prep filings for antifungal rezafungin

    Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in the coming months. The two partners say the ReSTORE trial of rezafungin, a drug in the echinocandin class, met its objectives in showing that rezafungin was as effective as daily dosing […]

  • Scynexis bids to end novel antifungal drought, filing ibrexafungerp in US

    Scynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be the first broad-spectrum antifungal to reach the US market for vaginal yeast infections in more than two decades. The Jersey City, US-based biotech has submitted ibrexafungerp (SCY-078) on schedule as a treatment for the vulvovaginal candidiasis (VVC), […]

  • Novo-backed $61m fundraising helps F2G prep for antifungal launch

    Anglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening fungal infections through late-stage development and onto the market. While these infections remain fairly rare, there is still a pressing need for new antifungals to provide treatment options when established therapies fail, and F2G is one of […]